Mira Pharmaceuticals (MIRA) Equity Average (2022 - 2025)

Mira Pharmaceuticals has disclosed Equity Average across 4 years of filings, most recently posting $9.0 million for Q4 2025.

• Equity Average for Q4 2025 came in at $9.0 million, up 210.04% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.0 million (up 210.04% YoY), and the FY2025 annual result was $6.3 million, up 91.66% from the prior year.
• Equity Average came in at $9.0 million for Q4 2025 at Mira Pharmaceuticals, up from $4.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $9.0 million in Q4 2025 to a low of -$1.2 million in Q1 2023.
• The 4-year median for Equity Average is $2.8 million (2024), against an average of $2.7 million.
• Across the five-year window, Equity Average surged 4628.8% in 2023 and tumbled 65.33% in 2025, its largest moves.
• Mira Pharmaceuticals' Equity Average stood at -$137891.5 in 2022, then soared by 4628.8% to $6.2 million in 2023, then slumped by 53.77% to $2.9 million in 2024, then surged by 210.04% to $9.0 million in 2025.
• The last three Equity Average figures came in at $9.0 million (Q4 2025), $4.0 million (Q3 2025), and $932012.0 (Q2 2025), per Business Quant data.